Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Extending Retreat Ahead of Tuesday Close

10/12/2021 | 03:58pm EST


ę MT Newswires 2021
All news about DECIPHERA PHARMACEUTICALS, INC.
11/25Analysis-Amid Bukele's bitcoin hype, not all Salvadorans 'Feel the Bit'
RE
11/23Deciphera's Qinlock Wins EU Nod For Gastrointestinal Cancer
MT
11/22Deciphera Pharmaceuticals Secures EU Nod for Gastrointestinal Stromal Tumor Drug Qinloc..
MT
11/22DECIPHERA PHARMACEUTICALS : Receives European Commission Approval of QINLOCK« for the Trea..
PU
11/22DECIPHERA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Other Events, Financial Statem..
AQ
11/22Deciphera Receives European Commission Approval of QINLOCK« for the Treatment of Fourth..
BU
11/22Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK? for T..
CI
11/18Seeking strength in numbers, U.S.-bound migrants in Mexico form new caravan
RE
11/10DECIPHERA PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
11/08JPMorgan Adjusts Price Target on Deciphera Pharmaceuticals to $10 From $43, Maintains N..
MT
More news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 95,3 M - -
Net income 2021 -290 M - -
Net cash 2021 73,0 M - -
P/E ratio 2021 -1,62x
Yield 2021 -
Capitalization 472 M 472 M -
EV / Sales 2021 4,19x
EV / Sales 2022 2,64x
Nbr of Employees 350
Free-Float 71,0%
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | DCPH | US24344T1016 | MarketScreener
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 8,07 $
Average target price 15,67 $
Spread / Average Target 94,1%
EPS Revisions
Managers and Directors
Steven L. Hoerter President, Chief Executive Officer & Director
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn Chief Scientific Officer & Executive VP
Stephen B. Ruddy Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.-85.86%472
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678